{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:30:41Z","timestamp":1787671841754,"version":"build-2736575974"},"reference-count":44,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Immunotherapies targeting B-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor (TNFR) superfamily, have demonstrated remarkable clinical efficacy in treating relapsed\/refractory multiple myeloma (MM). However, a major challenge is the frequent downregulation or loss of BCMA expression in patients receiving BCMA-targeted immunotherapies, which substantially diminishes therapeutic efficacy and contributes to disease progression and treatment resistance after an initial positive response. In this study, we developed a T-cell\u2013redirecting bispecific antibody (bsAb) targeting transmembrane activator and CAML interactor (TACI), another TNFR superfamily member expressed on MM cells. The TACI \u00d7 CD3 bsAb induced robust T-cell activation, proliferation, and potent cytotoxicity against MM cells. Importantly, it also effectively inhibited the growth of MM cells with downregulated BCMA expression that were unresponsive to BCMA \u00d7 CD3 bsAb treatment. Moreover, the TACI \u00d7 CD3 bsAb mediated effective cytotoxicity against primary MM cells derived from patients. Collectively, these findings suggest that TACI-targeted T-cell\u2013redirecting bsAb may represent a promising therapeutic strategy for MM, with the potential of overcoming resistance associated with BCMA downregulation in MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018210","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:52:37Z","timestamp":1780516357000},"page":"5669-5682","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Engineering a TACI \u00d7 CD3 bispecific antibody to redirect T cells against multiple myeloma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2405-8503","authenticated-orcid":false,"given":"Minchuan","family":"Zhang","sequence":"first","affiliation":[{"name":"1Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2438-2715","authenticated-orcid":false,"given":"Wai Fook","family":"Leong","sequence":"additional","affiliation":[{"name":"1Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-6537","authenticated-orcid":false,"given":"Jianxin","family":"Huo","sequence":"additional","affiliation":[{"name":"1Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5407-0280","authenticated-orcid":false,"given":"Eve Zi","family":"Xian Ngoh","sequence":"additional","affiliation":[{"name":"1Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1972-0190","authenticated-orcid":false,"given":"Hanping","family":"Loh","sequence":"additional","affiliation":[{"name":"2Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Chen","sequence":"additional","affiliation":[{"name":"3Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina H. M.","family":"Toh","sequence":"additional","affiliation":[{"name":"4Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"De Mel","sequence":"additional","affiliation":[{"name":"5National University Cancer Institute, Singapore, National University Health System, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-0655","authenticated-orcid":false,"given":"Melissa","family":"Ooi","sequence":"additional","affiliation":[{"name":"5National University Cancer Institute, Singapore, National University Health System, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinnie","family":"Soekojo","sequence":"additional","affiliation":[{"name":"5National University Cancer Institute, Singapore, National University Health System, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[{"name":"4Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore"},{"name":"5National University Cancer Institute, Singapore, National University Health System, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansheng","family":"Yang","sequence":"additional","affiliation":[{"name":"2Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1316-4333","authenticated-orcid":false,"given":"Kong-Peng","family":"Lam","sequence":"additional","affiliation":[{"name":"1Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore"},{"name":"6Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengli","family":"Xu","sequence":"additional","affiliation":[{"name":"1Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore"},{"name":"7Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"issue":"1","key":"2026082510523437600_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","article-title":"Current treatment landscape for relapsed and\/or refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"2026082510523437600_bib2","doi-asserted-by":"crossref","first-page":"820768","DOI":"10.3389\/fonc.2022.820768","article-title":"Gene expression profiling in multiple myeloma: redefining the paradigm of risk-adapted treatment","volume":"12","author":"Cerchione","year":"2022","journal-title":"Front Oncol"},{"issue":"7","key":"2026082510523437600_bib3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2026082510523437600_bib4","doi-asserted-by":"crossref","first-page":"e1339853","DOI":"10.1080\/2162402X.2017.1339853","article-title":"The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms","volume":"6","author":"Pazina","year":"2017","journal-title":"Oncoimmunology"},{"issue":"8","key":"2026082510523437600_bib5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2026082510523437600_bib6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2026082510523437600_bib7","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"16","key":"2026082510523437600_bib8","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1158\/1078-0432.CCR-20-3600","article-title":"Facts and hopes in multiple myeloma immunotherapy","volume":"27","author":"Sperling","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2026082510523437600_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/antib6040018","article-title":"monoclonal antibody: a new treatment strategy against multiple myeloma","volume":"6","author":"Cho","year":"2017","journal-title":"Antibodies (Basel)"},{"issue":"23","key":"2026082510523437600_bib10","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.3390\/cancers13236136","article-title":"Promising antigens for the new frontier of targeted immunotherapy in multiple myeloma","volume":"13","author":"Cho","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2026082510523437600_bib11","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/cancers12041045","article-title":"Transmembrane activator and CAML interactor (TACI): another potential target for immunotherapy of multiple myeloma?","volume":"12","author":"Xu","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"25","key":"2026082510523437600_bib12","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2026082510523437600_bib13","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/bi048227k","article-title":"Selectivity of BAFF\/BLyS and APRIL for binding to the TNF family receptors BAFFR\/BR3 and BCMA","volume":"44","author":"Day","year":"2005","journal-title":"Biochemistry"},{"key":"2026082510523437600_bib14","article-title":"FDA approves first BCMA-targeted therapeutic","year":"2020","journal-title":"Nature"},{"issue":"6","key":"2026082510523437600_bib15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med Overseas Ed"},{"issue":"6","key":"2026082510523437600_bib16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/2643-3230.BCD-23-0176","article-title":"An embarrassment of riches: three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma","volume":"4","author":"Firestone","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026082510523437600_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-025-01675-5","article-title":"BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting","volume":"18","author":"Zheng","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"15","key":"2026082510523437600_bib18","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/bloodadvances.2021004176","article-title":"Effective anti-BCMA retreatment in multiple myeloma","volume":"5","author":"Gazeau","year":"2021","journal-title":"Blood Adv"},{"key":"2026082510523437600_bib19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","article-title":"Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells","volume":"81","author":"Chen","year":"2019","journal-title":"Leuk Res"},{"issue":"suppl 1","key":"2026082510523437600_bib20","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully human BCMA targeted chimeric antigen receptor t cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2026082510523437600_bib21","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026082510523437600_bib22","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"2026082510523437600_bib23","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"12","key":"2026082510523437600_bib24","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"2026082510523437600_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026082510523437600_bib26","volume-title":"Society of Hematologic Oncology 2023 Annual Meeting (SOHO 2023)","author":"Harrison","year":"2023"},{"key":"2026082510523437600_bib27","doi-asserted-by":"crossref","first-page":"TPS8064","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064","article-title":"CAMMA 2: a phase I\/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent","volume":"41","author":"Kumar","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026082510523437600_bib28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2017-09-807610","article-title":"CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2026082510523437600_bib29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J"},{"issue":"9","key":"2026082510523437600_bib30","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"2026082510523437600_bib31","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"issue":"13","key":"2026082510523437600_bib32","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","article-title":"Role of B-cell\u2013activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"66","author":"Tai","year":"2006","journal-title":"Cancer Res"},{"issue":"7","key":"2026082510523437600_bib33","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2026082510523437600_bib34","doi-asserted-by":"crossref","first-page":"e006699","DOI":"10.1136\/jitc-2023-006699","article-title":"Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy","volume":"11","author":"Lee","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"11","key":"2026082510523437600_bib35","doi-asserted-by":"crossref","first-page":"e005091","DOI":"10.1136\/jitc-2022-005091","article-title":"Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization","volume":"10","author":"Camviel","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2026082510523437600_bib36","first-page":"138","article-title":"Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth","volume":"5","author":"Huo","year":"2022","journal-title":"Antib Ther"},{"issue":"3","key":"2026082510523437600_bib37","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","article-title":"The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature","volume":"106","author":"Moreaux","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2026082510523437600_bib38","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2026082510523437600_bib39","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4161\/19420862.2015.989013","article-title":"Production of bispecific antibodies in \"knobs-into-holes\" using a cell-free expression system","volume":"7","author":"Xu","year":"2015","journal-title":"MAbs"},{"issue":"4","key":"2026082510523437600_bib40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/antib13040097","article-title":"Development of BCMA-targeted bispecific natural killer cell engagers for multiple myeloma treatment","volume":"13","author":"Zhang","year":"2024","journal-title":"Antibodies"},{"issue":"1","key":"2026082510523437600_bib41","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1038\/s41467-023-43416-7","article-title":"Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma","volume":"14","author":"Larson","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"2026082510523437600_bib42","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2026082510523437600_bib43","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","article-title":"The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance","volume":"13","author":"Ferguson","year":"2022","journal-title":"Nat Commun"},{"issue":"suppl 1","key":"2026082510523437600_bib44","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2025-2811","article-title":"Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in relapsed\/refractory multiple myeloma","volume":"146","author":"Scott","year":"2025","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5669\/2537996\/blooda_adv-2025-018210-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5669\/2537996\/blooda_adv-2025-018210-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:58:49Z","timestamp":1787669929000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/16\/5669\/568864\/Engineering-a-TACI-CD3-bispecific-antibody-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":44,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018210","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,25]]},"published":{"date-parts":[[2026,8,14]]}}}